2-(3-methoxyphenyl)quinoline-4,6-diamine | 423184-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(3-methoxyphenyl)quinoline-4,6-diamine
• 英文别名: 2-(3-Methoxyphenyl)-4,6-quinolinediamine
• CAS: 423184-77-4
• 化学式: C₁₆H₁₅N₃O
• 分子量: 265.315
• InChiKey: BLEODXJPTOZHNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  74.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 2-(3-methoxyphenyl)quinoline-4,6-diamine 在 盐酸 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 为溶剂， 反应 10.0h， 以0.033 g的产率得到N6-[2-amino-6-(4-chlorophenyl)pyrimidin-4-yl]-2-(3-methoxyphenyl)quinoline-4,6-diamine
  参考文献：
  名称：

  Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents

  摘要：

  NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.

  DOI：

  10.1021/ml300134b
• 作为产物：
  描述：

  (3-甲氧基苯甲酰)乙酸乙酯 在 盐酸 、 sodium azide 、 乙醇 、 Dowtherm A 、 tin(ll) chloride 、 三氯氧磷 作用下， 以 N-甲基吡咯烷酮 、 乙酸乙酯 、 正丁醇 为溶剂， 反应 74.0h， 生成 2-(3-methoxyphenyl)quinoline-4,6-diamine
  参考文献：
  名称：

  Quinolinyl Pyrimidines: Potent Inhibitors of NDH-2 as a Novel Class of Anti-TB Agents

  摘要：

  NDH-2 is an essential respiratory enzyme in Mycobacterium tuberculosis (Mtb), which plays an important role in the physiology of Mtb. Herein, we present a target-based effort to identify a new structural class of inhibitors for NDH-2. High-throughput screening of the AstraZeneca corporate collection resulted in the identification of quinolinyl pyrimidines as the most promising class of NDH-2 inhibitors. Structure-activity relationship studies showed improved enzyme inhibition (IC50) against the NDH-2 target, which in turn translated into cellular activity against Mtb. Thus, the compounds in this class show a good correlation between enzyme inhibition and cellular potency. Furthermore, early ADME profiling of the best compounds showed promising results and highlighted the quinolinyl pyrimidine class as a potential lead for further development.

  DOI：

  10.1021/ml300134b

文献信息

• N-type calcium channel antagonists for the treatment of pain
  申请人：——

  公开号：US20040077644A1

  公开（公告）日：2004-04-22

  Compounds useful for the treatment of pain in accord with the following structural diagram, 1 wherein R 1 , R 2 and R 3 are any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.

  符合以下结构图的用于治疗疼痛的化合物，其中R1、R2和R3是根据规范定义的多种基团之一，以及利用这些化合物的药物组合物和治疗方法。
• N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN
  申请人：AstraZeneca AB

  公开号：EP1339688A1

  公开（公告）日：2003-09-03
• US7189714B2
  申请人：——

  公开号：US7189714B2

  公开（公告）日：2007-03-13
• US7348340B2
  申请人：——

  公开号：US7348340B2

  公开（公告）日：2008-03-25
• [EN] N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN<br/>[FR] ANTAGONISTES DU CANAL CALCIUM DE TYPE N POUR TRAITER LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2002036567A1

  公开（公告）日：2002-05-10

  Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R?1, R2 and R3¿ are any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.